Traditional protein design and validation methods are slow, expensive, and often yield proteins with limited functionality or stability. This inefficiency hinders the development of novel therapeutics and other biomedicine applications that rely on custom-engineered proteins.

Profluent leverages deep generative models to accelerate the design and validation of novel proteins. By applying advanced AI techniques to decode the underlying principles of protein structure and function, Profluent's platform enables the creation of proteins with enhanced properties and tailored functionalities. This approach significantly reduces the time and resources required for protein engineering, facilitating the development of innovative therapeutic solutions. The platform aims to overcome the limitations of traditional methods by predicting and optimizing protein sequences for desired characteristics, such as improved binding affinity, stability, or enzymatic activity.

Deep generative models for de novo protein sequence design

AI-driven prediction of protein structure and function

In silico validation of protein candidates

Optimization of protein sequences for desired properties

High-throughput screening capabilities

The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery, protein engineering, and other biomedicine applications.